The Agency of Health Technology Assessment and Tariff Systems was commissioned to assess the benefit for angioplasty of arteries of lower extremities (femoral and popliteal) with drug-eluting balloons in Poland

In December 2024, the Skåne University Hospital (HTA South) is working on health technology assessments in several areas, including men’s health and neurology.

In November 2024, the HTA body of the Tuscany Regional Healthcare published five rapid HTA reports (four new assessments and one reassessment) of medical devices in the cardiovascular, ophthalmology, ENT, and dermatology areas.

On October 24, 2024, the BfArM (Federal Institute for Drugs and Medical Devices) published the final version of the 2025 OPS procedure coding classification. The OPS, together with the ICD-10-GM (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification), forms the basis for the reimbursement systems in outpatient and inpatient care in Germany. Multiple new procedure codes were introduced in several fields, including cardiovascular, endoscopic, peripheral vascular, and robotic surgery.

In October 2024, the National Institute for Health and Care Research (NIHR) in England released seven Med Tech-related assessments in its HTA Journal, which concerned the Genedrive kit, timing of stoma closure in neonates, interventions in perceptual disorders after stroke, revascularisation strategy for chronic limb ischemia, MRI software and cognitive fusion biopsies in prostate cancer, transperineal prostate biopsy devices, and ultraviolet therapy in severe eczema. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs NICE guidance.

In late October 2024, the Agency for Health Technology Assessment and Tariff System (AOTMiT) published several recommendations concerning the Prenatal Testing Program, specifically on removing alpha-fetoprotein and estriol testing and qualifying the placental growth factor (PlGF) test and free fetal DNA testing (cffDNA) as part of non-invasive prenatal diagnostics.